{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"The number of patients who had a DLT during the dose finding/confirming portion (Phase I) of the trial for the safety of the combination of sirolimus, tacrolimus and lenalidomid. Patients will be monitored for 28 days (a cycle) to determine whether a DLT is experienced for the specific dose level.","groups":[{"description":"Standard treatment of sirolimus and tacrolimus as GvHD prophylaxis with sirolimus (target plasma drug level of 5-10 ng/ml) and lenalidomide (15 mg daily) as post-transplant maintenance","id":"OG000","title":"Phase I Dose Finding"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients assigned to Phase I and received treatment medication.","reportingStatus":"POSTED","timeFrame":"28 days","title":"Phase I: Number of Participants With Dose Limiting Toxicity","type":"PRIMARY","unitOfMeasure":"Participants"}